You are here » Home » Companies » Company Overview » Metropolis Healthcare Ltd

Metropolis Healthcare Ltd.

BSE: 542650 Sector: Health care
NSE: METROPOLIS ISIN Code: INE112L01020
BSE 00:00 | 19 Feb 1828.50 1.70
(0.09%)
OPEN

1827.00

HIGH

1889.95

LOW

1815.10

NSE 00:00 | 19 Feb 1825.85 0.35
(0.02%)
OPEN

1840.20

HIGH

1891.95

LOW

1811.50

OPEN 1827.00
PREVIOUS CLOSE 1826.80
VOLUME 10630
52-Week high 1950.00
52-Week low 904.85
P/E 72.56
Mkt Cap.(Rs cr) 9,179
Buy Price 1830.00
Buy Qty 12.00
Sell Price 1858.00
Sell Qty 1.00
OPEN 1827.00
CLOSE 1826.80
VOLUME 10630
52-Week high 1950.00
52-Week low 904.85
P/E 72.56
Mkt Cap.(Rs cr) 9,179
Buy Price 1830.00
Buy Qty 12.00
Sell Price 1858.00
Sell Qty 1.00

Metropolis Healthcare Ltd. (METROPOLIS) - Chairman Speech

Company chairman speech

Dear Shareholders

Putting our patients first: Delivering reliable pathology reports

It gives me immense satisfaction to pen down this message as the Chairman of MetropolisHealthcare Ltd. It has been a long and humbling journey for me personally to seeMetropolis grow as a reputed and trusted pathology brand all across India and markets inAfrica. I started out with a single minded focus on putting our patients first

and a relentless pursuit in delivering accurate results and quality reports. Ourscientific vision has remained constant and each day is a new step ahead in delivering theutmost customer experience; whether it is growing our test menu growing our network orjust being there for the patient at their most anxious times. Metropolis has also adoptedreflex testing policy for certain tests which require re-testing with a differenttechnology. Our promise to the patient is very simple; reliable pathology reports and forthat we walk the extra mile for recheck and reflex at no additional cost to our patients.

Working in tandem with doctors because pathology matters

More than 70% of medical decisions today are based on diagnostic reports. My team ofdoctors is constantly in touch with clinicians work in tandem and help them diagnose andmake treatment decisions for their patients. Be it a simple blood sugar test or acomplicated molecular genetic test we have built in all the capabilities to deliver theabsolute best.

Building our test menu

Metropolis has always been at the forefront in bringing new tests and technologies tothe people. As of March 2019 our test menu comprised of 3487 clinical laboratory testsand over 530 test profiles. The profile comprises of a variety of test combinations whichare specific to a disease or disorder as well as wellness profiles that are used forhealth and fitness screening. This is a true testament to the scientific core of thecompany.

Quality: A way of functioning at Metropolis

Metropolis has a dedicated quality assurance team that works on accreditations for ourvarious centers. Our Global Reference Laboratory in Mumbai is accredited by CAP (Collegeof American Pathologists) a reputed global accreditation board and NABL (NationalAccreditation Board for Testing & Calibration Laboratories). To give a perspective tothe benefit of our shareholders our CAP Proficiency Testing Scores are above 98%indicating consistently good proficiency. Proficiency Testing score is indicative ofquality results delivered by laboratory thereby insuring quality patient care. I am proudthat our

PT (Proficiency Testing) score puts Metropolis amongst the top 2% of laboratoriesworldwide.

Metropolis is the only private laboratory to have in-house developed and NABLaccredited EQAS program. This program is used to monitor analytical quality of our grouplabs and 115 group labs is covered currently and is ready for commercial launch forcustomers.

Gearing up for Sustainable Goals and Reporting

Our CSR activities are focused in areas of Education Health Gender Equality andEmpowerment. One of our core CSR programmes Medengage is exclusively focused on nurturingthe medical talent in the country by way of certificate courses observership programmesenabling them to pursue academic papers and also scholarship benefits for deservingstudents. Our goal from hereon will be to align to sustainable goals integrate these into our core business function.

On a closing note FY19 has been an exhilarating year for us and in FY20 our only hopeas always is to impact patient lives positively by way of accurate pathology reportsempathetic patient-centric approach and being there for our patients.

On behalf of the Board of Directors of Metropolis I thank all our shareholdersemployees bankers and various stakeholders for the trust and confidence shown in us andwe look forward to your continued support.

Warm regards

Dr Sushil Shah

Founder & Chairman